ライフサイエンスコーパス: gastrointestinal stromal tumour

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 with placebo after the resection of primary gastrointestinal stromal tumour.

2 y be performed in all patients with advanced gastrointestinal stromal tumour.

3 ective in first-line treatment of metastatic gastrointestinal stromal tumour.

4 lacebo after resection of localised, primary gastrointestinal stromal tumour.

5 d with sunitinib in patients with metastatic gastrointestinal stromal tumours.

6 transformation of ICC and the development of gastrointestinal stromal tumours.

7 pared with placebo in patients with advanced gastrointestinal stromal tumour after failure and discon

8 in the treatment of recurrent or metastatic gastrointestinal stromal tumours and is now being tested

9 atients with unresectable imatinib-resistant gastrointestinal stromal tumour are available.

10 Gastrointestinal stromal tumours are the most common mes

11 ts had complete gross resection of a primary gastrointestinal stromal tumour at least 3 cm in size an

12 nts with metastatic renal-cell carcinoma and gastrointestinal stromal tumours, but concerns have aris

13 The phase III trial in advanced gastrointestinal stromal tumour, EORTC 62005, demonstrat

14 approved as third-line therapy for advanced Gastrointestinal Stromal Tumour (GIST) at a starting dos

15 Gastrointestinal stromal tumour (GIST) is the most commo

16 ave proven clinical benefit in patients with gastrointestinal stromal tumours (GIST), but almost all

17 l (RFS) after resection of localised primary gastrointestinal stromal tumours (GIST).

18 initiating events, fostering hyperplasia in gastrointestinal stromal tumours (GISTs), and additional

19 in KIT or PDGFRalpha are key drivers in most gastrointestinal stromal tumours (GISTs).

20 Gastrointestinal stromal tumour is the most common sarco

21 on of isolated metastatic colorectal cancer, gastrointestinal stromal tumours, neuroendocrine cancers

22 apparent antitumour activity was noted in a gastrointestinal stromal tumour, papillary thyroid cance

23 Gastrointestinal stromal tumour patients with exon 9 KIT

24 e intracellular Bcr-Abl tyrosine kinase, and gastrointestinal stromal tumours, where it targets eithe

25 kinase inhibitor, in patients with advanced gastrointestinal stromal tumour who were resistant to or

26 atients with imatinib-resistant, metastatic, gastrointestinal stromal tumours who had been enrolled i

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。